SCHEMBL14375226

SCHEMBL14375226

CC1CCN(Cc2cn(C)c3ccccc23)CC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.64
GLA P06280 1/20 0.64
HDAC8 Q9BY41 1/20 0.60
HDAC6 Q9UBN7 1/20 0.60
ALDH1A1 P00352 3/20 0.59
TSHR P16473 1/20 0.59
ACHE P22303 5/20 0.58
DRD2 P14416 2/20 0.55
DRD4 P21917 2/20 0.55
DRD3 P35462 2/20 0.55
GPR84 Q9NQS5 1/20 0.54
SMN1; SMN2 Q16637 2/20 0.52
KDM4E B2RXH2 1/20 0.52
ALOX15 P16050 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
HSD17B10 Q99714 1/20 0.52
BCHE P06276 1/20 0.49
HTR2A P28223 1/20 0.49
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15084330 0.83 LMNA (0.55) LMNAGLAHDAC8HDAC6ALDH1A1
SCHEMBL5961922 0.83 LMNA (0.69) LMNAGLAHDAC8HDAC6ALDH1A1
SCHEMBL8473238 0.81 LMNA (0.66) LMNAGLAHDAC8HDAC6ALDH1A1
SCHEMBL2162689 0.78 LMNA (1.00) LMNAGLAALDH1A1TSHRDRD2
SCHEMBL15081946 0.75 OPRL1 (0.53) LMNAGLAHDAC8HDAC6ALDH1A1
SCHEMBL5196972 0.74 LMNA (0.81) LMNAGLAALDH1A1TSHRDRD2
SCHEMBL22619052 0.74 DRD2 (0.58) HDAC8HDAC6DRD2DRD4DRD3
SCHEMBL5881100 0.71 GPR84 (1.00) LMNAGLAALDH1A1TSHRGPR84
SCHEMBL6976015 0.71 LMNA (0.48) LMNAGLAHDAC8HDAC6ALDH1A1
SCHEMBL12013922 0.71 ACHE (1.00) LMNAALDH1A1ACHEDRD2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070244133-A1 Thienopyrimidines and Thiazolopyrimidines for Use in Medicine ASTRAZENECA AB (SE) 2007-10-18 US disclosed
US-20070244133-A1 Thienopyrimidines and Thiazolopyrimidines for Use in Medicine ASTRAZENECA AB (SE) 2007-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244133-A1 Thienopyrimidines and Thiazolopyrimidines for Use in Medicine CXCR4, CXCR1, CXCR3 LMNA 4739/4885GLA 3920/4885HDAC8 3582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.